Comparative efficacy and safety of potassium-competitive acid blockers and proton pump inhibitors for erosive esophagitis: a network meta-analysis of randomized controlled trials - PubMed
4 hours ago
- #P-CABs
- #erosive esophagitis
- #PPIs
- The study compares potassium-competitive acid blockers (P-CABs) and proton pump inhibitors (PPIs) for treating erosive esophagitis (EE).
- Vonoprazan 20 mg, zastaprazan 20 mg, and esomeprazole 40 mg showed the highest efficacy for healing EE at 8 weeks.
- Vonoprazan 10 mg and 20 mg, along with esomeprazole 20 mg, were most effective in preventing recurrence at 24 weeks.
- Benefits were most pronounced in Los Angeles (LA) grade C/D EE cases.
- Safety profiles between P-CABs and PPIs were generally comparable at 8 and 24 weeks.
- The study highlights the need for further trials comparing newer P-CABs with optimized PPI strategies, including twice-daily dosing.
- The evidence supporting these findings is of moderate to high certainty.